Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Eli LillyLargest US-listed GLP-1 franchise via Mounjaro (T2D) and Zepbound (obesity). Retatrutide (triple agonist) in Phase 3; orforglipron (oral non-peptide) expected FDA decision Q2 2026. Also major diabetes, oncology, and immunology portfolios.
2020-2025
Q2 2022-Q3 2025
2021-Q2-2026-Q1
2021-Q2-2026-Q1
1993-2025
$LLY
Largest US-listed GLP-1 franchise. Mounjaro (T2D) and Zepbound (obesity) drove Q1 2026 revenue growth of 56% with Mounjaro +125% and Zepbound +80%. Retatrutide (triple agonist) in Phase 3; orforglipron (oral non-peptide) expected FDA decision Q2 2026. LillyDirect cash-pay channel launched January 2024.